Biktarvy Efficacy and Recommendations for HIV-1 Infection

Clinical Recommendations and Guidelines

The International Antiviral Society-USA Panel lists Biktarvy (bictegravir/TAF/emtricitabine) as a generally recommended initial regimen for HIV-1 treatment (evidence rating AIa) 1
In patients who acquire HIV-1 while taking PrEP (TXF/XTC), bictegravir in combination with TXF/XTC can be started before resistance testing results are available 2
For patients with viral suppression and previous treatment failure with archived resistance mutations, Biktarvy may be effective even in the presence of M184V/I mutations 3
Biktarvy is not currently recommended with rifampin due to drug-drug interactions and inadequate data (evidence rating: AIII) 2
Biktarvy should not be used during pregnancy due to inadequate data to support its use (evidence rating: AIII) 4

Biktarvy has minimal drug-drug interactions compared to other antiretroviral classes, making it a preferred option when co-administered with other medications 5

Regular monitoring of HIV viral load is essential to ensure continued virological suppression 5